Oliveira Douglas V N P, Zhang Shanshan, Chen Xin, Calvisi Diego F, Andersen Jesper B
a Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences , University of Copenhagen , Copenhagen N , Denmark.
b Department of Bioengineering and Therapeutic Sciences and Liver Center , University of California , San Francisco , CA , USA.
Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):349-356. doi: 10.1080/17474124.2017.1292127. Epub 2017 Feb 13.
Intrahepatic cholangiocarcinoma (iCCA) is the second most frequent primary tumor of the liver and a highly lethal disease. Therapeutic options for advanced iCCA are limited and ineffective due to the largely incomplete understanding of the molecular pathogenesis of this deadly tumor. Areas covered: The present review article outlines the main studies and resulting discoveries on the molecular profiling of iCCA, with a special emphasis on the different techniques used for this purpose, the diagnostic and prognostic markers identified, as well as the genes and pathways that could be potentially targeted with innovative therapies. Expert commentary: Molecular profiling has led to the identification of distinct iCCA subtypes, characterized by peculiar genetic alterations and transcriptomic features. Targeted therapies against some of the identified genes are ongoing and hold great promise to improve the prognosis of iCCA patients.
肝内胆管癌（iCCA）是肝脏第二常见的原发性肿瘤，是一种高致死性疾病。由于对这种致命肿瘤的分子发病机制了解大多不完整，晚期iCCA的治疗选择有限且效果不佳。涵盖领域：本综述文章概述了关于iCCA分子谱分析的主要研究及相关发现，特别强调了用于此目的的不同技术、已鉴定的诊断和预后标志物，以及可能通过创新疗法靶向的基因和信号通路。专家评论：分子谱分析已导致识别出不同的iCCA亚型，其特征为独特的基因改变和转录组特征。针对一些已鉴定基因的靶向治疗正在进行中，有望显著改善iCCA患者的预后。
